A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined Inclusion/exclusion criteria could apply
Capital Federal, Buenos Aires 1264, Argentina
Capital Federal, Buenos Aires 1280, Argentina
Ciudad Autonoma Buenos Aires, Distrito Federal 1118, Argentina
CABA, 1426, Argentina
Itacorubi, Florianopolis, Santa Catarina 88034, Brazil
Sao Jose de Rio Preto, São Paulo 15091-000, Brazil
Avignon Cedes 9, 84918, France
Wilton, CORK 0, Ireland
Suita-shi, Osaka 565-0871, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Chuo-ku, Tokyo 1040045, Japan
Koto-ku, Tokyo 1358550, Japan
Minato-ku, Tokyo 1058470, Japan
Shinjuku-ku, Tokyo 1600023, Japan
Shinjuuku-ku, Tokyo 1608582, Japan
Kita-gun, 7610793, Japan
Maastrict, 6229 HX, Netherlands
Songpa-gu, Seoul 05505, South Korea